Genetic and Inflammatory Signatures Associated With Worse Prognosis in Hospitalized Patients With Severe SARS‐CoV‐2 Infection With and Without Diabetes
Journal of Medical Virology · 2025
DOI: 10.1002/jmv.70425 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Marshall Yuan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Robert Wood Johnson Medical School, Piscataway, New Jersey, USA. Hauptthemen laut MEDLINE: COVID-19, Diabetes Mellitus. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported in part by a research grant from Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp., Merck.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SAR‐CoV‐2) presents with a diverse symptomology, ranging from asymptomatic to severe disease, but the mechanism of risk factors such as diabetes remains unelucidated. The current retrospective cohort study of 182 patients, with and without COVID‐19 and diabetes, analyzed leftover blood specimens for RNA sequencing and chemokine/cytokine, ACE2/DPP‐IV concentrations. After analysis, 14 223 genes had sufficient hits; 18 genes and 431 genes were differentially expressed between patients with and without COVID‐19 and patients with and without diabetes, respectively. Both analyses had differentially expressed five genes, GRASP, KRT8, MYZAP, PRKG1, and SMIM24. DPP‐IV concentrations were statistically lower in COVID‐19 patients versus non‐COVID‐19, but no significant differences in chemokine/cytokine expression and ACE2 concentrations were detected. This study provides insight into altered gene expression patterns in individuals with COVID‐19 with and without diabetes mellitus and highlights potential markers for severe disease and pathways for treatment targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Robert Wood Johnson Medical School, Piscataway, New Jersey, USA.
- Department of Pharmaceutics, Ernest Mario School of Pharmacy, Piscataway, New Jersey, USA.
- Johnson & Johnson, Translational Medicine and Early Development Statistics, Raritan, New Jersey, USA.
- Department of Statistics, Rutgers University, Piscataway, New Jersey, USA.
- IDCare, Hillsborough, New Jersey, USA.
- Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, USA.
ORCID-Profile: Marshall Yuan
Förderung
- This study was supported in part by a research grant from Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp.
- Merck
Zitieren
APA
Yuan, M., Wassef, A., Sargsyan, D., Nersisyan, V., Cabrera, J., Nahass, R. G., Hassan, W., Kong, A. N., & Brunetti, L. (2025). Genetic and Inflammatory Signatures Associated With Worse Prognosis in Hospitalized Patients With Severe SARS‐CoV‐2 Infection With and Without Diabetes. Journal of Medical Virology. https://doi.org/10.1002/jmv.70425
Vancouver
Yuan M, Wassef A, Sargsyan D, Nersisyan V, Cabrera J, Nahass RG, et al. Genetic and Inflammatory Signatures Associated With Worse Prognosis in Hospitalized Patients With Severe SARS‐CoV‐2 Infection With and Without Diabetes. Journal of Medical Virology. 2025. doi:10.1002/jmv.70425
BibTeX
@article{Yuan2025,
author = {Yuan, Marshall and Wassef, Andrew and Sargsyan, Davit and Nersisyan, Vahe and Cabrera, Javier and Nahass, Ronald G and Hassan, Wael and Kong, Ah-Ng and Brunetti, Luigi},
title = {Genetic and Inflammatory Signatures Associated With Worse Prognosis in Hospitalized Patients With Severe SARS‐CoV‐2 Infection With and Without Diabetes},
journal = {Journal of Medical Virology},
year = {2025},
doi = {10.1002/jmv.70425}
}
EUVIMED